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A B S T R A C T
Recent studies have linked cell-free mitochondrial DNA (ccf-mtDNA) to neurodegeneration in both Alzheimer's
and Parkinson's disease, raising the possibility that the same phenomenon could be seen in other diseases which
manifest a neurodegenerative component. Here, we assessed the role of circulating cell-free mitochondrial DNA
(ccf-mtDNA) in end-stage progressive multiple sclerosis (PMS), where neurodegeneration is evident, contrasting
both ventricular cerebral spinal fluid ccf-mtDNA abundance and integrity between PMS cases and controls, and
correlating ccf-mtDNA levels to known protein markers of neurodegeneration and PMS. Our data indicate that
reduced ccf-mtDNA is a component of PMS, concluding that it may indeed be a hallmark of broader neurode-
generation.
1. Introduction
Progressive multiple sclerosis (PMS) is a chronic, inflammatory,
demyelinating disorder with progressive neurodegeneration
(Stadelmann, 2011). Inflammation is an inducer of neuronal damage
which, with chronic demyelination, leads to loss of central nervous
system (CNS) tissue. White matter demyelination is a cardinal hallmark
of PMS, although neuropathological studies also indicate extensive
axonal loss in the spinal cord tracts and synapses of the gray matter
(Bjartmar et al., 2003; Jurgens et al., 2016).
MS has an established link to mitochondrial dysfunction (Witte
et al., 2014). At the cellular level, mitochondrial dysfunction plays a
direct role in demyelination, with mitochondrial structural changes,
altered gene expression and mitochondrial enzyme activities observed
in MS patients (Mao and Reddy, 2010a). At the genetic level, inherited
mitochondrial DNA (mtDNA) variation modulates MS risk (Andalib
et al., 2013), with mtDNA haplogroups (distinct monophyletic clades of
mtDNA variants) both increasing (haplogroup J) (Tranah et al., 2015)
and decreasing (haplogroup K) (Hudson et al., 2014) the risk of de-
veloping MS. Multiple deletions of mtDNA, typically indicative of pri-
mary mitochondrial disease, can be detected in the gray matter of MS
cases (Campbell et al., 2011).
In mammals, mtDNA appears more resistant to degradation by nu-
cleases than nDNA (Manuelidis, 2011) and appears to persist in extra-
cellular fluids as circulating, cell-free, mtDNA (ccf-mtDNA). ccf-mtDNA
appears associated with neurodegeneration, with significant decreases
in ccf-mtDNA observed in the cerebrospinal fluid (CSF) of patients with
Parkinson's disease (PD) (Pyle et al., 2015a) and Alzheimer's disease
(AD) (Podlesniy et al., 2013). Conversely, elevated CSF ccf-mtDNA
appears associated with traumatic brain injury in children (Podlesniy
et al., 2013) and recent investigations of ccf-mtDNA in MS, focusing on
individuals alive at CSF biopsy, identified increased ccf-mtDNA copies
in both relapsing-remitting MS (RRMS) (Varhaug et al., 2017)and PMS
(Leurs et al., 2017); with elevated ccf-mtDNA appearing associated with
brain atrophy (Leurs et al., 2017).
To date, there are no accurate predictors of neurodegeneration in
MS. (Harris et al., 2017) The identification of markers which could
inform neurodegenerative risk would be useful to both existing ther-
apeutic strategies, but could also be used to inform future MS clinical
trials (Harris et al., 2017). Given the links between MS progression and
mitochondrial DNA (Campbell et al., 2011; Campbell and Mahad, 2018)
and previous evidence linking ccf-mtDNA to other neurodegenerative
diseases (Pyle et al., 2015a; Podlesniy et al., 2013), we analysed the ccf-
mtDNA present in the post mortem ventricular CSF (vCSF) of PMS cases
where neurodegeneration is more pronounced, comparing both ccf-
mtDNA abundance and integrity to matched controls. In addition, we
assessed the levels of known neurodegenerative disease (glial fibrillary
acidic protein and S100 calcium binding protein B) (Petzold et al.,
2003; Yardan et al., 2011; Avsar et al., 2012; Michetti et al., 2012) and
PMS protein markers (Chitinase 3 like 1 and Chitinase 3 like 2)
(Sellebjerg et al., 2017; Hinsinger et al., 2015), correlating protein le-
vels to ccf-mtDNA copies in both PMS cases and controls. We
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hypothesised that, similar to other neurodegenerative diseases such as
AD and PD, CSF ccf-mtDNA levels would be significantly lower in PMS
cases with evidence of neurodegeneration, indicating that a reduction
in ccf-mtDNA in the CSF is a component of neurodegenerative disease.
2. Materials and methods
2.1. Subjects
36 PMS (30% male, mean age at death 63 ± 12 years) and 43
matched control (54% male, mean age at death 78 ± 10 years) ven-
tricular CSF (vCSF) samples were obtained from The UK MS Society
Tissue Bank (Imperial College, London). All vCSF samples were pre-
pared (i.e. to remove cells) as described previously (Pyle et al., 2015a;
Mollenhauer et al., 2008). Briefly, vCSF was centrifuged (2000 g for
10min) at room temperature, aliquoted into CSF collection tubes and
stored upright at −80 °C. PMS was diagnosed in-life and confirmed
neuropathologically (UK MS Society Tissue Bank, Imperial College,
London). All controls were negative for the hallmarks of disease-related
neurodegeneration or inflammation. Importantly, we saw no significant
differences in age at death, brain weight post mortem interval or mal-
e:female ratio between PMS cases and controls, summarised in Sup-
plementary Table 1.
2.2. mtDNA copy and deletion quantification
Mitochondrial DNA was quantified using established methods
(previously described in (Pyle et al., 2015a; Grady et al., 2014; Pyle
et al., 2016). Briefly, two mitochondrial regions, MTND1, MTND4
(Supplementary Fig. 2) and a nuclear encoded housekeeping gene,
B2M, were amplified and assayed in triplicate by multiplex Taqman
mediated qPCR as per manufacturer's guidelines (ThermoFisher Scien-
tific, primers: MTND1 forward 5′-ACGCCATAAAACTCTTCACCAAAG-3′
and reverse 5′-GGGTTCATAGTAGAAGAGCGATGG-3′, MTND4 forward
5′-ACCTTGGCTATCATCACCCGAT-3′ and reverse: 5′-AGTGCGATGAGT
AGGGGAAGG-3′, and B2M forward 5′-CACTGAAAAAGATGAGTAT
GCC-3′ and reverse 5′- AACATTCCCTGACAATCCC-3′). As in previous
work (Coxhead et al., 2016), mtDNA primer efficiency and specificity
was assessed as accurate after zero amplification of DNA from Rho0
(mtDNA depleted) cell lines, avoiding the unintended amplification of
nuclear pseudogenes. mtDNA level is calculated as an absolute mea-
surement of MTND1 derived from a triplicated standard curve and is
expressed as copies per 1 μl of CSF. mtDNA deletion level, expressed as
a ratio of MTND1 to MTND4 as described previously (Pyle et al., 2015a;
Grady et al., 2014; Pyle et al., 2016). mtDNA deletions, as in previous
work (Grady et al., 2014), were limited to those> 10%; to account for
the sensitivity and specificity of qPCR to reliably detect mtDNA dele-
tions.
2.3. mtDNA deep-sequencing
Deep sequencing and subsequent bioinformatic analysis of mtDNA
extracted from a subset of vCSF samples (12 PMS and 22 controls, 41%
of samples) was performed as previously described (Coxhead et al.,
2016). Briefly, DNA was extracted from vCSF using Ultrapure™ (phe-
nol:chloroform:isoamyl alcohol) and ethanol precipitation as per man-
ufacturer's instructions (SigmaAldritch). mtDNA was enriched using
three overlapping long-range PCR amplicons covering the entire
mtDNA genome (set 1, m.3016-9201, forward 5′-CAGCCGCTATTAAA
GGTTCG-3′ and reverse: 5′-GTTGTCGTGCAGGTAGAGG-3′; set 2,
m.8656-14,857, forward 5′-ACCACCCAACAATGACTAATC-3′ and re-
verse 5′-GGTTGTTTGATCCCGTTTCG-3′, and set 3, m.14797-3574,
forward 5′-ATTCATCGACCTCCCCACC-3′ and reverse: 5′-GGAGGGGG
GTTCATAGTAG-3′) and was amplified using PrimeSTAR GXL DNA
Polymerase as per manufactures guidelines (Takara Bio Company). As
in previous work (Coxhead et al., 2016), mtDNA primer efficiency and
specificity was assessed as accurate after zero amplification of DNA
from Rho0 (mtDNA depleted) cell lines, avoiding the unintended am-
plification of nuclear pseudogenes. In 59% (47 out of 81) of vCSF
samples, mtDNA enrichment was hindered by low mtDNA template
availability. Subsequent PCR products were purified, pooled and pre-
pared using Illumina Nextera XT Library preparation kit using manu-
facturers guidelines (Illumina, USA). Libraries were pooled using the
MiSeq Reagent Kit and the Illumina MiSeq v3.0 sequencing platform
(Illumina, USA) in paired-end, 250 bp reads. Post-run FASTQ files were
analysed using an established bioinformatic pipeline as previously de-
scribed (Coxhead et al., 2016). Homoplasmic variation was defined
as> 99% Heteroplasmic variation was defined as> 1% and < 99%.
Variant comparisons, i.e. mutational burden were made between PMS
case and control CSF ccf-mtDNA.
2.4. Protein quantification
Glial fibrillary acidic protein (GFAP) and S100 calcium binding
protein B (S100β), previously used to indicate neurodegeneration
(Petzold et al., 2003; Yardan et al., 2011), and PMS (Avsar et al., 2012;
Michetti et al., 2012) were measured in all samples with sufficient vCSF
(27 PMS and 15 controls, 51% of samples) using western blot, with
protein levels normalised to total protein level measured with BLOT-
FastStain™. Chitinase 3 like 1 (CHI3L1), used to differentiate active and
inactive PMS (Sellebjerg et al., 2017), and Chitinase 3 like 2 (CHI3L2),
used to differentiate PMS and RRMS (Hinsinger et al., 2015), were
measured by ELISA (Cusabio, YKL-40 and R&D systems DC3 L10, re-
spectively) in the same samples as above (i.e. 27 PMS and 15 controls)
as per manufacturers guidelines.
2.5. Statistical analysis
Data was analysed using SPSS v22 and Prism v5 using data appro-
priate tests (detailed in the text). Statistical significance was set at
p < .05. Heteroplasmic Ka/Ks is expressed as a ratio of non-synon-
ymous (Ka) to synonymous (Ks) heteroplasmic variants (Li et al., 1985).
3. Results
a) Analysis of vCSF ccf-mtDNA in PMS
Similar to our previous work (Pyle et al., 2015a), and the work of
others (Podlesniy et al., 2013; Varhaug et al., 2017; Leurs et al., 2017),
we limited our analysis to samples harbouring< 1 copy of a house-
keeping gene (B2M) to minimise the perceived contamination of cells or
cellular debris in the vCSF; reducing our cohort to 14 PMS cases (38%)
and 25 controls (58%). Using these criteria we identified a significant
reduction of vCSF ccf-mtDNA level in PMS cases compared to controls
(Wilcoxon Ranked Sum Test p= .013, mean rank ccf-mtDNA in 14 PMS
cases was 16.4 and in 25 controls was 26.9, Fig. 1a).
However, recent reports show evidence of cell free-nuclear DNA
(ccf-nDNA) in the CSF (Adalsteinsson et al., 2017; Connolly et al.,
2017), suggesting that nDNA contamination may not necessarily be a
result of carryover of cells or a product of cellular debris during DNA
extraction. In addition, the existing literature suggests that ccf-mtDNA
resists degradation whilst ccf-nDNA does not (Manuelidis, 2011),
raising the possibility that ccf-nucleic acids are still a consequence of
cellular degradation, but whilst the ccf-nDNA has been degraded, the
ccf-mtDNA has persisted. Therefore we removed the B2M threshold
from our analysis, continuing to identify a significant decrease of vCSF
ccf-mtDNA copies in PMS cases compared to controls (Wilcoxon Ranked
Sum Test p= .0023, mean rank ccf-mtDNA in 36 PMS cases was 30.4
and in 43 controls was 45.8, Fig. 1b).
To investigate further, we tested the effect of B2M level on ccf-
mtDNA level in PMS using logistic regression, confirming our previous
association between PMS and ccf-mtDNA when including B2M level as
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a covariate (p= .004), identifying no significant correlation between
B2M levels and ccf-mtDNA levels (r2= 2.5× 10−7 and p=99,
Supplementary Fig. 1) and no significant difference in B2M levels be-
tween PMS cases and controls (Wilcoxon Ranked Sum Test p > .05).
Given that B2M levels do not appear to effect ccf-mtDNA abun-
dance, and to increase sample size and statistical power, all subsequent
analysis will refer to the full dataset (36 PMS cases and 43 controls).
Linear regression showed no significant association (p > .05) between
ccf-mtDNA and age at death, brain weight, post mortem interval (in
PMS cases, controls or combined) or age of onset and disease duration
(PMS cases only), and we found no significant association (Logistic
regression p > .05) between ccf-mtDNA and sex (in PMS cases, con-
trols or combined, summarised in Supplementary Table 2).
b) ccf-mtDNA integrity in PMS vCSF
mtDNA deletions have been observed in PMS neuronal tissue
(Campbell et al., 2011). We were able to identify mtDNA deletions
(> 10% deleted mtDNA) (Grady et al., 2014) in a minority of our
samples (5 out of 36, or 13%, PMS cases and 9 out of 43, or 20%,
controls), indicating that ccf-mtDNA is intact in the majority of samples
(Supplementary Fig. 2). However we found no significant difference in
ccf-mtDNA deletion levels between PMS cases and controls (Wilcoxon
Ranked Sum Test p > .05, Fig. 2a) and no significant correlation
(p > .05) between ccf-mtDNA deletion level and age at death, brain
weight, post mortem interval (in either PMS cases, controls or when
combined) or age of onset (PMS cases only) (Supplementary Table 2).
Next generation sequencing of ccf-mtDNA identified heteroplasmic
variation in all 34 vCSF samples used. Although mutation frequency
appeared higher in PMS cases compared to controls, the comparison
was not significant (Wilcoxon Ranked Sum Test p > .05, mean and
standard deviation of total heteroplasmic mutation frequency in 12
PMS cases was 1.6×10−3 ± 9×10−4 and 1.4×10−3 ± 1×10−3
in 22 controls, Fig. 2b and Supplementary Table 3).
Further stratification by variant type (e.g. D-loop variants, tRNA
variants etc) revealed an increase in non-synonymous variation (mean
heteroplasmic non-synonymous mutation frequency in PMS cases was
1.1×10−3and was 7.4×10−4 in controls) and a decrease in synon-
ymous variation (mean heteroplasmic non-synonymous mutation fre-
quency in PMS cases was 5.x10−4and was 9.7×10−4 in controls)
between PMS cases and controls, although no comparison reached
statistical significance (p > .05, Supplementary Fig. 3 and
Supplementary Table 3).
Under the hypothesis that ccf-mtDNA export may be a product of
Fig. 1. Comparison of ccf-mtDNA copies between
PMS cases and controls. The plots depict the com-
parison of ccf-mtDNA copies (per μl vCSF) between
PMS cases (shaded) and matched controls (un-
shaded): a) with a B2M threshold of< 1 copy ap-
plied (where mean ccf-mtDNA copies in 14 PMS
cases was 1678.0, SEM of 298.4, and 2876.2, SEM of
317.0, in 25 controls) and, b) without a B2M
threshold applied (where mean ccf-mtDNA copies in
36 PMS cases was 2412.7, SEM of 327.5, and 3784.7,
SEM of 356.4, in 43 controls), where ** and *** in-
dicate Wilcoxon Ranked Sum Test significance at
p < .05 and p < .005 respectively.
Fig. 2. Analysis of ccf-mtDNA integrity in
PMS cases and controls. The plots depict: a)
comparative ccf-mtDNA deletions (> 10%)
detected in PMS cases and matched controls
(mean deletion in 5 PMS cases was 16.8,
SEM of 4.2, and 20.5, SEM of 2.8, in 9
controls), b) the comparative total hetero-
plasmic mutation frequency (heteroplasmy
per bp sequenced) in PMS cases and con-
trols (mean total heteroplasmic mutation
frequency in 12 PMS cases was 2.6×10−3,
SEM of 7.1× 10−4, and 2.2× 10−3, SEM
of 4.3× 10−4, in 22 controls). c) total
heteroplasmic mutation frequency versus
ccf-mtDNA copies for PMS cases and mat-
ched controls combined (12 PMS cases and
22 controls), and d) the comparative Ka/Ks
for PMS cases and matched controls (mean
Ka/Ks in 12 PMS cases was 1.9, SEM of
0.28, and 0.99, SEM of 0.17, in 22 controls),
where *** indicates Wilcoxon Ranked Sum
Test significance at p < .005.
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normal mtDNA maintenance, we compared total heteroplasmic varia-
tion frequency to ccf-mtDNA level, but found no significant correlation
(p > .05, Fig. 2c). Further, we found no significant correlation be-
tween total heteroplasmic mutation burden and age at death, brain
weight, post mortem interval (in either PMS cases, controls or when
combined) or age of onset (PMS cases only), summarised in Supple-
mentary Table 2.
We did identify a significant difference in heteroplasmy Ka/Ks ratio,
a correction used as an estimate of the degree of evolutionary constraint
(Li et al., 1985), between PMS cases and controls (Wilcoxon Ranked
Sum Test p= .0022, Fig. 2d); with PMS ccf-mtDNA having a higher
proportion of non-synonymous to synonymous variation compared to
controls. However, we found no significant correlation (p > .05) be-
tween Ka/Ks ratio and ccf-mtDNA level in either PMS cases, controls or
when combined and no correlation between Ka/Ks ratio and age at
death, brain weight, post mortem interval (in either PMS cases, controls
or when combined) or age of onset (PMS cases only), summarised in
Supplementary Table 2.
c) ccf-mtDNA and neurodegeneration
Increased S100β is indicative of neurodegeneration (Rothermundt
et al., 2003) and vCSF levels were significantly higher in PMS cases
versus controls, (Wilcoxon Ranked Sum Test p= .040, mean and
standard deviation in PMS cases was 0.99 ± 1.0 and 0.17 ± 0.48 in
controls (Fig. 3a and Supplementary Table 4), with 14 out of 27 PMS
cases (51%) and 12 out of 15 controls (80%) exhibiting undetectable
levels.
Increased CSF levels of GFAP is indicative of neurodegeneration
(Petzold et al., 2003) and increased levels have been observed on PMS
patients (Avsar et al., 2012). We observed an increase of GFAP in PMS
cases compared to control (Fig. 3b), although this did not reach sta-
tistical significance (Wilcoxon Ranked Sum Test p > .05, mean and
standard deviation in PMS cases was 0.53 ± 0.0.90 and 0.16 ± 0.22
in controls), with 11 out of 27 PMS cases (41%) and 6 out of 15 controls
(40%) exhibiting undetectable levels.
CSF CHI3L1 and CHI3L1 are elevated in PMS compared to controls
(Hinsinger et al., 2015), with CHI3L1:CHI3L2 ratio reportedly having
superior predictive accuracy than individual measures (Hinsinger et al.,
2015). However, neither CHI3L1, CHI3L2 nor CHI3L1:CHI3L2 ratio
were significantly different between PMS cases and matched controls
when analysed together or as a ratio (Wilcoxon Ranked Sum Test
p > .05, Figs. 3c-e and Supplementary Table 4).
However, ultimately, we saw no significant correlation between
vCSF ccf-mtDNA and the levels of S100β, GFAP, CHI3L1, CHI3L2 or
CHI3L1:CHI3L2 ratio when analysed as PMS cases only or controls only,
or when combined (Supplementary Table 2).
4. Discussion
Our results indicate that vCSF ccf-mtDNA is significantly reduced in
post-mortem PMS cases compared to controls which, when taken into
context with observations in both Parkinson's disease (PD) (Pyle et al.,
2015a) and Alzheimer's disease (AD) (Podlesniy et al., 2013), supports
our hypothesis that ccf-mtDNA may be an component of neurodegen-
eration. After assessing mtDNA integrity, we conclude that ccf-mtDNA
is largely intact, with few cases and controls harbouring mtDNA dele-
tions. Interestingly we did observe a shift in the proportion of non-sy-
nonymous variation in the ccf-mtDNA of PMS cases compared to con-
trols, which may be a product of ccf-mtDNA export, but which did not
correlate to PMS or PMS-related phenotypic data. Ultimately, however,
neither ccf-mtDNA level nor integrity correlated to protein markers of
neurodegeneration.
Despite our observations, and an increasing amount of literature
reporting associations between ccf-mtDNA levels and disease (> 25
publications since 2014, PubMed keyword search using combinations
Fig. 3. Comparison of neurodegenerative protein levels between PMS cases and controls. The plots depict the comparative levels of the neurodegenerative proteins
S100β, GFAP, CHI3L1 and CHI3L2 (a to d) detected in 27 PMS cases and 15 controls and e) the relative ratio of CHI3L1 to CHI3L2 in PMS cases and controls, where
** indicates Wilcoxon Ranked Sum Test significance at p < .05.
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of ‘cell’ ‘free’ ‘mitochondrial’ ‘DNA’ and appropriate abbreviations), we
know little of the underlying causes of mtDNA export to intracellular
spaces, therefore we opted to study the integrity of the ccf-mtDNA,
contrasting PMS cases to controls.
It is possible that, assuming that mtDNA export is a normal proce-
dure (as it occurs in control samples and typically at higher levels) (Pyle
et al., 2015a; Podlesniy et al., 2013; Melentijevic et al., 2017), the lower
levels seen in neurodegenerative disease is a direct consequence of a
pre-existing cellular mtDNA depletion in vulnerable brain regions. This
hypothesis is supported by previous studies showing tissue specific
depletion of mtDNA in PD patients, (Pyle et al., 2015b; Grunewald
et al., 2016) AD patients (Rice et al., 2014; Rodriguez-Santiago et al.,
2001), and MS patients (Mao and Reddy, 2010b; Dutta et al., 2006; Ban
et al., 2008; Blokhin et al., 2008a); indicating that low ccf-mtDNA
observed in the vCSF of these cases is possibly a result of neuronal
mtDNA levels which are already compromised prior to export.
Alternatively, it is possible that the release of mtDNA into in-
tracellular spaces is a quality control mechanism, where mutant mtDNA
is expelled to maintain mitochondrial function. This hypothesis is
supported by recent neuronal work in C. elegans, which expel dys-
functional mitochondria when exposed to neurotoxic stress
(Melentijevic et al., 2017). Further, the ependymal epithelium of the
ventricles and choroid plexus have abundant mitochondrial content due
to the high energy demand of transepithelial transport (Cornford et al.,
1997). The majority of these mitochondria are located at the apical
brush border (Spector et al., 2015), the most likely site of expulsion of
whole mitochondria or cell-free mtDNA into the CSF during normal cell
turnover or through active vesicular transport. Our data appear to
support this hypothesis in part. Our investigations indicate that vCSF
ccf-mtDNA is predominantly intact, with few samples showing mea-
surable deletion levels, and although NGS analysis indicates the pre-
sence of heteroplasmic variation, we observed a non-significant in-
crease in total heteroplasmic mutation and non-synonymous burden
between PMS cases and controls. We did observe an imbalance in the
Ka/Ks ratio between PMS cases and controls, with PMS cases exhibiting
a greater than expected ratio of non-synonomous:synonymous varia-
tion, which may indicate that ccf-mtDNA export may be a selective
process; where the ‘wild-type’ mtDNA molecule is retained in the cell
and the ‘mutant’ mtDNA molecule is preferentially exported. This hy-
pothesis supported by recent work in MS indicating that the neuronal
tissues of cases harbour relatively few mtDNA mutations compared to
matched controls (Blokhin et al., 2008b),although further work would
be needed to be definitive.
Contrary to our findings, increased levels of ccf-mtDNA have been
observed in the CSF of both RRMS (Varhaug et al., 2017) and PMS
(Leurs et al., 2017). This is perhaps not unexpected in RRMS, which is
an acutely inflammatory disease which precedes the neurodegenerative
processes characteristic of PMS (Kingwell, 2009). It is possible there-
fore, that the increase in ccf-mtDNA observed in RRMS is a direct result
of an increase in inflammatory cells which, in addition to nuclear DNA,
release mtDNA into the CSF (Frank, 2016).
Leur's et al. (2018) (Leurs et al., 2017) report an increase of lumbar
CSF (lCSF) ccf-mtDNA in PMS cases compared to controls. Given the
parity in cohort sizes (40 PMS and 23 controls to our 36 PMS and 43
controls) the discrepancy between our results is unlikely to be a factor
of statistical power. It is possible that the difference in CSF sampling
may explain the discordance between results, with their samples taken
in-life and ours taken post-mortem, and as the composition of vCSF may
be different from lCSF in normal circumstances and under severe pa-
thological conditions (Gerber et al., 1998; Sommer et al., 2002).
However we observed no correlation between post mortem interval or
brain weight to ccf-mtDNA levels in either PMS cases, controls or the
cohorts combined, suggesting that the latter is not the case. Further, the
increase in PMS ccf-mtDNA reported by Leurs et al. (2018) (Leurs et al.,
2017) is limited to a small proportion of PMS cases (~30%) and the
majority of PMS cases and controls exhibited ccf-mtDNA copies below
the levels we observed in our study and other previously published lCSF
mtDNA levels (typically 20–400 copies per microliter CSF in cases and
20–300 copies per microliter in controls in previous reports) (Podlesniy
et al., 2013; Melentijevic et al., 2017; Pyle et al., 2015c). Our overall
comparably higher ccf-mtDNA levels could be attributed to the in-
creased autolysis or pleoctytosis which occurs in post-mortem CSF
(Morris et al., 2012; Bardale, 2009), however we observed a significant
reduction in ccf-mtDNA copies in PMS cases, despite no significant
difference in PMI, brain weight or B2M levels between PMS cases and
controls and no correlation between ccf-mtDNA and ccf-B2M levels,
suggesting that this is not the case. It should be noted that, unlike Leurs
et al. (2018) (Leurs et al., 2017), we were unable to assess the effect of
ccf-mtDNA on brain atrophy directly.
With the exception of S100β, protein markers of neurodegeneration
and PMS appeared uninformative when comparing cases and controls.
Although GFAP and CHI3L1 appeared elevated in PMS cases compared
to controls, the differences did not reach statistical significance.
Further, we observed no obvious stratification of PMS cases using
CHI3L1:CHI3L2 ratio, further indication that our cases were indeed all
PMS cases (Hinsinger et al., 2015).Never the less, we observed no
correlation between protein markers of neurodegeneration and ccf-
mtDNA level or integrity; although this may reflect the late disease
stage of our cases and the use of post-mortem CSF.
5. Conclusion
In conclusion, and excepting limitations, our findings support our
hypothesis that decreased ccf-mtDNA may be an indicator of neurode-
generation in PMS. Although we observed a significant association, we
urge caution. In light of previous work (Varhaug et al., 2017; Leurs
et al., 2017), we cannot exclude the possibility that ccf-mtDNA levels
rise in-life in response to the onset of disease and then reduce as neu-
rodegeneration increases, however longitudinal assessments in PMS
cases would be needed to assess this. Therefore, whilst reduced ccf-
mtDNA may be a hallmark of the presence of neurodegeration, it is not
particularly useful as a biomarker, even with a more detailed analysis.
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